Period Invested for | ₹1000 SIP Started on | Investments | Latest Value | Abs. Returns |
---|---|---|---|---|
One Week | 2025-05-27 | ₹1,000.00 | ₹996.83 |
-0.32 %
|
Two Week | 2025-05-19 | ₹1,000.00 | ₹992.40 |
-0.76 %
|
1 Month | 2025-05-05 | ₹1,000.00 | ₹1,004.34 |
0.43 %
|
Three Months | 2025-03-05 | ₹3,000.00 | ₹3,104.33 |
3.48 %
|
Six Months | 2024-12-05 | ₹6,000.00 | ₹5,998.72 |
-0.02 %
|
One Year | 2024-06-03 | ₹12,000.00 | ₹12,401.00 |
3.34 %
|
Since Inception | 2024-04-26 | ₹14,000.00 | ₹14,628.46 |
4.49 %
|
Company Name | Sector | Sector Type | Nav(in %) |
---|---|---|---|
Poly Medicure Ltd. | Healthcare Equipment & Supplies | Equity | 1.67 |
Max Healthcare Institute Ltd. | Healthcare Services | Equity | 13.48 |
Fortis Healthcare Ltd. | Healthcare Services | Equity | 5.17 |
Syngene International Ltd. | Healthcare Services | Equity | 2.90 |
Dr. Lal Path Labs Ltd. | Healthcare Services | Equity | 2.24 |
Krishna Institute Of Medical Sciences Ltd. | Healthcare Services | Equity | 2.07 |
Global Health Ltd. | Healthcare Services | Equity | 2.04 |
Narayana Hrudayalaya Ltd. | Healthcare Services | Equity | 1.68 |
Rainbow Childrens Medicare Ltd. | Healthcare Services | Equity | 1.17 |
Aster Dm Healthcare Ltd. | Healthcare Services | Equity | 1.10 |
Metropolis Healthcare Ltd. | Healthcare Services | Equity | 1.07 |
Lupin Ltd. | Pharmaceuticals & Biotechnology | Equity | 9.13 |
Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 7.98 |
Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 5.27 |
Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 4.34 |
Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 3.70 |
Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Equity | 3.61 |
Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 3.48 |
Biocon Ltd. | Pharmaceuticals & Biotechnology | Equity | 3.18 |
Abbott India Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.99 |
Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.92 |
J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.72 |
Suven Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.50 |
Natco Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.44 |
Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.32 |
Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.19 |
Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.12 |
Granules India Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.69 |
Alembic Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.28 |
Sanofi India Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.17 |
Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.42 |
India's "lock-in period" in mutual funds encourages long-term investment, particularly in tax-saving schemes preventing redemption or selling of units.
Lock-in times for various investment types
Residual maturity is the remaining time until a security reaches its maturity date. It is an important factor for investors to consider when evaluating the risk associated with an investment.
There are two different types of residual maturity.
Scheme Name | 1Y Return | 3Y Return | SI Return |
---|---|---|---|
HDFC Nifty 100 ETF |
9.88%
|
5.38%
|
9.06%
|
LIC MF Nifty Midcap 100 ETF - GROWTH |
9.84%
|
8.76%
|
14.28%
|
Baroda BNP Paribas NIFTY Bank ETF - Regular Plan - Growth |
9.82%
|
4.80%
|
10.75%
|
KOTAK NIFTY SDL PLUS AAA PSU BOND JUL 2028 60:40 INDEX FUND - Regular Plan - Growth |
9.79%
|
11.04%
|
8.27%
|
DSP NiftySDLPlus G-SecJun2028 30:70IndexFund -Regular Plan - Growth Mat.Dt.30-06-2028 |
9.75%
|
12.42%
|
6.99%
|
BARODA BNP PARIBAS BANKING AND PSU BOND FUND - REGULAR PLAN - GROWTH |
9.70%
|
11.06%
|
5.46%
|
DSP Nifty 50 Equal Weight ETF |
9.58%
|
33.13%
|
14.03%
|
Kotak Nifty Commodities Index Fund Regular Plan - Growth |
9.54%
|
4.66%
|
60.82%
|
ICICI Prudential Nifty SDL Sep 2027 Index Fund - Growth |
9.49%
|
12.24%
|
6.70%
|
ICICI Prudential Nifty PSU Bond Plus SDL Sep 2027 40:60 Index Fund Growth |
9.34%
|
11.84%
|
5.95%
|
Scheme Name | 1Y Return | 3Y Return | SI Return |
---|---|---|---|
Tata Corporate Bond Fund - Regular Plan - Growth |
9.80%
|
11.64%
|
6.39%
|
Tata Nifty SDL Plus AAA PSU Bond Dec 2027 60: 40 Index Fund - Regular Plan - Growth |
9.46%
|
12.02%
|
6.95%
|
Tata Floating Rate Fund - Regular Plan - Growth |
9.26%
|
11.44%
|
6.50%
|
Tata Young Citizens Fund - Regular Plan - Growth |
9.24%
|
28.65%
|
4.87%
|
Tata Retirement Savings Fund - Progressive Regular Plan - Growth |
9.20%
|
30.47%
|
14.75%
|
Tata Equity Savings Fund - Regular Plan - Growth |
9.18%
|
16.41%
|
7.51%
|
Tata Multi Asset Opportunities Fund - Regular Plan - Growth |
9.00%
|
24.90%
|
17.36%
|
Tata Short Term Bond Fund - Regular Plan - Growth |
8.80%
|
10.78%
|
7.11%
|
Tata Nifty G-Sec Dec 2026 Index Fund - Regular Plan - Growth |
8.27%
|
8.85%
|
7.53%
|
Tata Nifty Capital Markets Index Fund Regular Plan Growth |
7.99%
|
3.92%
|
18.17%
|
Interested in exploring more about JezzMoney Mutual Fund Distributors Software? Submit the form, and we will respond quickly.